Wellington Management Group LLP Invests $1.70 Million in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Wellington Management Group LLP acquired a new position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 158,674 shares of the biotechnology company's stock, valued at approximately $1,704,000. Wellington Management Group LLP owned about 0.19% of Anavex Life Sciences as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in the stock. Wealth Enhancement Advisory Services LLC boosted its position in shares of Anavex Life Sciences by 69.4% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 26,673 shares of the biotechnology company's stock valued at $286,000 after acquiring an additional 10,925 shares during the last quarter. PVG Asset Management Corp boosted its holdings in Anavex Life Sciences by 503.5% in the 4th quarter. PVG Asset Management Corp now owns 78,490 shares of the biotechnology company's stock valued at $843,000 after purchasing an additional 65,485 shares during the last quarter. Vermillion Wealth Management Inc. acquired a new position in Anavex Life Sciences in the 4th quarter valued at about $34,000. Squarepoint Ops LLC grew its stake in shares of Anavex Life Sciences by 304.9% in the 4th quarter. Squarepoint Ops LLC now owns 67,627 shares of the biotechnology company's stock valued at $726,000 after buying an additional 50,924 shares during the period. Finally, ProShare Advisors LLC raised its position in shares of Anavex Life Sciences by 31.0% during the 4th quarter. ProShare Advisors LLC now owns 25,147 shares of the biotechnology company's stock valued at $270,000 after buying an additional 5,958 shares during the period. 31.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

AVXL has been the subject of several analyst reports. HC Wainwright reiterated a "buy" rating and issued a $42.00 price objective on shares of Anavex Life Sciences in a research report on Monday, April 7th. D. Boral Capital reiterated a "buy" rating and set a $46.00 price target on shares of Anavex Life Sciences in a report on Monday, April 7th.

Anavex Life Sciences Price Performance

Shares of NASDAQ:AVXL traded up $0.49 during mid-day trading on Friday, reaching $8.27. 1,187,633 shares of the company were exchanged, compared to its average volume of 1,218,316. The firm has a market cap of $706.03 million, a price-to-earnings ratio of -15.04 and a beta of 0.82. Anavex Life Sciences Corp. has a 1 year low of $3.51 and a 1 year high of $14.44. The firm's 50-day simple moving average is $8.42 and its 200 day simple moving average is $9.08.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.03. During the same period last year, the firm earned ($0.13) earnings per share. On average, research analysts forecast that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current fiscal year.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.